Danirixin

CAS No. 954126-98-8

Danirixin( GSK-1325756 )

Catalog No. M16816 CAS No. 954126-98-8

Danirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 222 In Stock
10MG 313 In Stock
25MG 529 In Stock
50MG 754 In Stock
100MG 1044 In Stock
500MG 2088 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Danirixin
  • Note
    Research use only, not for human use.
  • Brief Description
    Danirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8).
  • Description
    Danirixin (GSK-1325756) is a high-affinity, selective and reversible CXCR2 antagonist (IC50=12.5 nM, CXCL8); blocks the CD11b upregulation with pIC50 of 6.05 and 6.3, respectively, in rat and human whole-blood studies; blocks the influx of neutrophils into the lung in vivo in rats following aerosol lipopolysaccharide (ED50=1.4 mg/kg); orally active.COPD Phase 2 Clinical(In Vitro):Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.
  • In Vitro
    Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.
  • In Vivo
    ——
  • Synonyms
    GSK-1325756
  • Pathway
    GPCR/G Protein
  • Target
    Chemokine Receptor
  • Recptor
    CXCL8-CXCR2
  • Research Area
    Inflammation/Immunology
  • Indication
    COPD

Chemical Information

  • CAS Number
    954126-98-8
  • Formula Weight
    441.9041
  • Molecular Formula
    C19H21ClFN3O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 8 mg/mL
  • SMILES
    ClC(C(S([C@H]1CCCNC1)(=O)=O)=C2O)=CC=C2NC(NC3=CC=CC(F)=C3C)=O
  • Chemical Name
    Urea, N-[4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl]-N'-(3-fluoro-2-methylphenyl)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bloomer JC, et al. Eur J Pharm Biopharm. 2017 Apr 3. pii: S0939-6411(16)31009-8. 2. Miller BE, et al. BMC Pharmacol Toxicol. 2015 Jun 20;16:18. 3. Busch-Petersen J, et al. J Pharmacol Exp Ther. 2017 Aug;362(2):338-346.
molnova catalog
related products
  • α-NETA

    A small molecule CMKLR1 antagonist that inhibits chemerin-stimulated β-arrestin2 association with CMKLR1 (EC50=9.7 nM).

  • AZD 1678

    AZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4.

  • (R)-CCX-777

    A small-molecule partial agonist of CXCR7 (ACKR3).